Evie Carchman, MD, FACS
- Division of Colorectal Surgery
- Administrative Assistant: (608) 263-2521
Clinical Science Center
600 Highland Avenue
Madison, WI 53792-7375
- MD, Medical College of Virginia at Virginia Commonwealth University, Richmond, VA, 2006
- General Surgery Residency, University of Pittsburgh Medical Center, Pittsburgh, PA, 2013
- Colon and Rectal Surgery Fellowship, Cleveland Clinic, Cleveland, OH, 2014
Dr. Evie Carchman is a fellowship-trained colon and rectal surgeon. She has special expertise in the treatment of colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease. Dr. Carchman utilizes minimally invasive techniques including laparoscopic and single incision laparoscopic surgery for the treatment of colon and rectal disease.
Dr. Carchman provides a wide range of services including Abdominoperineal Resection, Abscess Drainage, Endorectal Advancement Flap, Fistulotomy, Flap Repair, Hemorrhoid Banding, Hemorrhoidectomy, Ileocolic Resection, Laparoscopic and Open Partial Colectomy, Laparoscopic and Open Rectopexy, Laparoscopic and Open Sigmoid Resection, Laparoscopic and Open Total Colectomy, Lateral Internal Sphincterotomy, Lower Anterior Resection (LAR), Pilonidal Cyst Excision, Sphincter Repair (overlapping sphincteroplasty), Total Proctocolectomy, Transanal Proctosigmoidectomy.
Dr. Carchman’s research interests focus on the pathogenesis and treatment of anal cancer. She has special expertise in the treatment of colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease. Dr. Carchman utilizes minimally invasive techniques including laparoscopic and single incision laparoscopic surgery for the treatment of colon and rectal disease.
Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors.
Gunder LC, Moyer TH, Johnson HR, Auyeung AS, Leverson GE, Zhang W, Matkowskyj KA, Carchman EH
J Surg Res 2023 Feb; 282: 137-146
[PubMed ID: 36274448]
The use of a topical protease inhibitor, Saquinavir, to alleviate mouse papillomavirus-mediated anal disease.
Gunder LC, Johnson HR, Green HA, Bilger A, Moyer TH, Zhang W, Ziolkowski MR, Bertrang PA, Carchman EH
Virology 2022 Nov; 576: 96-104
[PubMed ID: 36206607]
Efficacy of Topically Administered Dihydroartemisinin in Treating Papillomavirus-Induced Anogenital Dysplasia in Preclinical Mouse Models.
Gunder LC, Blaine-Sauer S, Johnson HR, Shin MK, Auyeung AS, Zhang W, Leverson GE, Ward-Shaw ET, King RE, McGregor SM, Matkowskyj KA, Lambert PF, Carchman EH
Viruses 2022 Jul 26; 14(8)
[PubMed ID: 35893697]
Do immune inflammatory markers correlate with anal dysplasia and anal cancer risk in patients living with HIV?
Stem J, Yang Q, Carchman E, Striker R, Sanger CB
Int J Colorectal Dis 2022 May; 37(5): 983-988
[PubMed ID: 35332364]
PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia.
Gunder LC, Moyer TH, Rademacher BL, Auyueng AS, Leverson G, Zhang W, Matkowskyj KA, Carchman EH
Exp Mol Pathol 2022 Apr; 125: 104752
[PubMed ID: 35183509]